NCT02680535View on ClinicalTrials.gov

MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Neoplasms of the Prostate
Interventions
DEVICE

AuroShell particle infusion

Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.

Trial Locations (5)

10019

Icahn School of Medicine at Mount Sinai, New York

21287

Johns Hopkins Hospital, Baltimore

48109

University of Michigan, Ann Arbor

77030

University of Texas Medical School at Houston, Houston

77555

The University of Texas Medical Branch, Galveston

Sponsors
All Listed Sponsors
lead

Nanospectra Biosciences, Inc.

INDUSTRY

NCT02680535 - MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue | Biotech Hunter | Biotech Hunter